OS07.4 Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified (EGFRamp), recurrent glioblastoma (rGBM)

Background: Patients (pts) with rGBM have a poor prognosis. EGFRamp is present in ~50% of GBMs. ABT-414 is an ADC that releases a potent toxin, monomethyl auristatin F (MMAF), inside cells with EGFRamp. Here we report the safety and efficacy of ABT-414 monotherapy at the recommended phase 2 dose (RP...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: van den Bent, M., Gan, H., Lassman, A., Kumthekar, P., Butowski, N., Nabors, L., Simes, J., Maag, D., Reardon, D.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
ORAL PRESENTATIONS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5463590/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.045
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados